The CD1d-binding glycolipid α-GalCer is recognized as a member of a new class of adjuvants and its adjuvanticity has been investigated for vaccines against tumors and various infectious diseases, including influenza (Gonzalez-Aseguinolaza et al., 2002; Ko et al., 2005; Youn et al., 2007; Choi et al., 2008; Huang et al., 2008, 2013; Guillonneau et al., 2009; Kopecky-Bromberg et al., 2009; Kim et al., 2010; Miller et al., 2011; Lu et al., 2014; Artiaga et al., 2016). Here, CD1D is linked to infectious disease.